Davos — Leaders of the global pharmaceutical industry, accused by US president-elect Donald Trump of "getting away with murder" on drug prices, are putting a brave face on challenges in their biggest market. The following are comments from CEOs on US pricing prospects, based on Reuters interviews at this week’s World Economic Forum in Davos. Joe Jimenez, Novartis "The new administration has been pretty vocal about supporting innovation. They understand that when you spend money on research and you develop intellectual property there needs to be some level of return for that investment. I believe, based on who the president-elect has put in place around him, that there is a clear understanding of investment and return on investment." Ken Frazier, Merck "Pricing will remain a challenging issue for those of us who are in the research-based pharmaceutical industry, as well as a challenge for the overall healthcare system in terms of what it can afford. The tweets will be what they will ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.